E-drug: Zenith Goldline (cont)
---------------------------------------------
Gloria Blumenthal questioned why there was no listing of the Zenith
form of generic furosemide in the PDR.
The PDR compiles FDA-approved labeling of pharmaceutical products on
a manufacturer by manufacturer basis, paid for by each manufacturer.
It is not an official compendium. Firms like Zenith that make
generic drugs have little or no economic incentive to pay the space
rates for listing in the PDR.
Typically their products are dispensed at a pharmacist's option when the
physician writes furosemide, or even with the original Hoechst
trademark, LASIX.
One of the hidden costs of having cheap generic drugs is sparse
information on the pharmaceutical products in question..
John Urquhart, MD, FRCP(Edin)
Professor of Pharmacoepidemiology, Maastricht University, Maastricht, NL
Chief Scientist, AARDEX Ltd/APREX Corp, Zug CH & Union City, CA, USA
Professor of Biopharmaceutical Sciences, UCSF, San Francisco
home office: 975 Hamilton Ave, Palo Alto, CA 94301 USA
email: urquhart@ix.netcom.com
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.